Filing Flows › Theravance Biopharma (TBPH) › Q4 2025
Theravance Biopharma (TBPH) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 23, 2026
Theravance Biopharma (TBPH) reported revenue of $45.9M for the fourth quarter 2025 (Q4 2025), +145% from a year earlier and +130% from the quarter before. Operating margin was 43.6%, net earnings $61.0M (133.0% of revenue).
Theravance Biopharma, Q4 2025: revenue $45.9M (+145% year over year), operating margin 43.6%, net earnings $61.0M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45.9M | +130% | +145% |
| Operating profit | $20.0M | — | — |
| Net earnings | $61.0M | 17× | — |
| Operating cash flow | −$6.1M | — | — |
What changed
Revenue was $45.9M in Q4 2025, up 145% year over year and up 130% from the previous quarter.
Operating profit was $20.0M, a 43.6% margin (up 92.7 points year over year). Total costs fell 7% while revenue rose 145%. Net earnings were $61.0M. The effective tax rate was 16.5%. Non-operating items added $53.1M, 73% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$6.1M. Non-cash charges added back $4.5M of share-based compensation. Working capital and other items used $71.6M. Capital expenditures of $8K exceeded it, leaving free cash flow of −$6.1M.
Questions
What was Theravance Biopharma's revenue in the fourth quarter 2025?
Theravance Biopharma (TBPH) reported revenue of $45.9M for the fourth quarter 2025 (Q4 2025), +145% from a year earlier and +130% from the quarter before.
Was Theravance Biopharma profitable in the fourth quarter 2025?
Operating profit was $20.0M (43.6% of revenue) and net earnings $61.0M.